PHOENIX: Axovant Sciences Ltd announced an expansion of its dementia drug development pipeline with the acquisition of nelotanserin and the addition of three new clinical programs to address cognitive, behavioural and functional aspects of Lewy body dementia. The Company also provided an update on its ongoing Phase 3 development program for RVT-101 to treat Alzheimer’s disease.